Metsera Inc
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
U.S. President Donald Trump attends an event to make an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming […]
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday. […]
Read More
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Metsera on Tuesday said Novo Nordisk‘s new […]
Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]
Read More
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to […]
Read More
Stocks making the biggest moves midday: Cigna, FormFactor, Meta Platforms, Microsoft, Carvana & more
Check out the companies making the biggest moves midday: Cigna — Shares of the health insurance company after management said during an earnings call that it expects its pharmacy benefit services division to face margin pressure in the next few years. Cardinal Health — The drug and medical equipment distributor surged more than 12% on […]
Read More
Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Denmark’s Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the fast-growing and competitive weight-loss drug market. Novo Nordisk, the company behind blockbuster weight loss drug Wegovy and diabetes […]
Read More